Diagnosis; Objective RespOnse; THErApy

Exclusion Criteria

• •1. Patients with concomitant CNS and systemic involvement at presentation (potentially eligible as "control"; see below)
• •2. Patients with CNS lymphoma other than DLBCL subtype
• •3. Any other serious medical condition which could impair the ability of the patient to participate in the trial
• •4. Pregnant and lactating female patients. Sexually active patients of childbearing potential must implement adequate contraceptive measures during study participation.
• •5. Previous or concurrent malignancies at other sites diagnosed or relapsed within the last 3 years before PCNSL diagnosis. Patients with surgically cured in situ carcinomas and basal cell carcinoma of the skin are allowed.
• •6. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
• •1. Patients with extra-CNS lymphoma other than DLBC or HGBC subtypes, and not classified as high risk of CNS relapse;
• •2. Any other serious medical condition which could impair the ability of the patient to participate in the trial;
• •3. Pregnant and lactating female patients. Sexually active patients of childbearing potential must implement adequate contraceptive measures during study participation;
• •4. Previous or concurrent malignancies at other sites diagnosed or relapsed within the last 3 years of follow-up. Patients with surgically cured in situ carcinomas and basal cell carcinoma of the skin are allowed;
• •5. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.